Carebook Technologies (CRBK) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 37% year-over-year to $3.7M (CAD 3.7 million), driven by expansion in employer health and wellness and pharmacy solutions, as well as organic growth and large implementations.

• Annual recurring revenue (ARR) reached $12.1M as of June 30, 2024, up 14% year-over-year, with 63% from clients outside Canada.

• Adjusted EBITDA loss improved to $(0.1)M, with margin improving to -3% from -9% in Q2 2023.

• Loss from operations improved to $(0.5)M from $(0.7)M year-over-year, reflecting higher revenue and cost optimization.

• Net loss remained stable at $(0.7)M compared to Q2 2023.

Financial highlights

• Revenue for Q2 2024 was $3.7M, up from $2.7M in Q2 2023, with 65% from the employer vertical and 35% from pharmacy.

• ARR reached $12.1M as of June 30, 2024, up 14% year-over-year.

• Adjusted EBITDA loss for Q2 2024 was $(0.1)M, compared to $(0.2)M in Q2 2023.

• Loss from operations improved by $0.2M, from $(0.7)M to $(0.5)M year-over-year.

• Adjusted EBITDA margin improved to -3% from -9% in Q2 2023.

Outlook and guidance

• Management expects continued organic revenue growth in 2024, especially in the employer vertical, though at a slower pace in coming quarters.

• Focus remains on cost management to minimize cash burn and increase profit margins.

• Company aims to achieve Adjusted EBITDA break-even or better in fiscal 2024.

• Plans to pursue accretive acquisitions and partnerships to complement organic growth and expand market reach.

• Pharmacy revenue anticipated to remain stable in 2024 but may decline thereafter.